# US 2013/0295203 A1 · Methods and compositions for the treatment of neuropsychiatric disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0295203 A1
- Document ID: US20130295203A1
- Status: Published application
- Kind: A1
- Application number: 13/937,168
- Filed: 2013-07-08
- Published: 2013-11-07
- Earliest claimed: 2010-08-16
- Inventors: Jay L. LOMBARD
- Web page: https://patentgrep.com/patent/US20130295203A1

## CPC

- A61K 31/685: one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A23L 33/10: using additives (addition of substantially indigestible substances A23L33/21)
- A61K 31/185: Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids (hydroxamic acids A61K31/16; peroxy acids A61K31/327)
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/197: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205)
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/201: having one or two double bonds, e.g. oleic, linoleic acids
- A61K 31/232: having three or more double bonds, e.g. etretinate
- A61K 31/26: Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K 31/375: Ascorbic acid, i.e. vitamin C; Salts thereof
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61K 33/06: Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

Methods and compositions are disclosed to treat neuropsychiatric disorders based upon a new framework of diagnosis. Axis I biomarkers include genes related to prefrontal dopamine synthesis and/or dopamine degradation. Axis II includes genes related to re uptake of dopamine, norepinephrine and serotonin and autonomic hyperactivity. Axis III includes genes relates to impairments in inflammatory pathways, glutamate neurotransmission and/or neurotrophic factors. Axis IV includes genes related to glutamate reuptake and predisposition to addictive behavior, and obsessive compulsions.

## Claims

### Claim 1

A method of treating a patient having a disruption in a prefrontal dopamine axis (Axis I) with a medical food, the method comprising providing the patient with a medical food composition comprising a first compound that reduces degradation of dopamine and a second compound that increases synthesis of dopamine.

### Claim 2 (depends on 1)

The method of claim 1, further comprising determining that the patient has a disruption in the prefrontal dopamine axis.

### Claim 3 (depends on 1)

The method of claim 1, further comprising determining that the patient has a disruption in the prefrontal dopamine axis based by identifying one or more biomarkers indicating a disruption in the prefrontal dopamine axis.

### Claim 4 (depends on 1)

The method of claim 1, further comprising determining that the patient has a disruption in the prefrontal dopamine axis based by identifying a disruption in the patient's catechol methyltransferase pathway(s).

### Claim 5 (depends on 1)

The method of claim 1, further comprising determining that the patient has a disruption in the prefrontal dopamine axis based by identifying a polymorphism in the patient's COMT gene, MTHFR gene or both COMT and MTHFR genes leading to a decrease in dopamine.

### Claim 6 (depends on 1)

The method of claim 1, wherein providing the first compound that reduces degradation of dopamine comprises phosphatidylserine.

### Claim 7 (depends on 1)

The method of claim 1, wherein providing the second compound that increases synthesis of dopamine comprises methylfolate.

### Claim 8 (depends on 1)

The method of claim 1, wherein providing the patient with a medical food composition comprises providing the patient with a medical food composition comprising phosphatidylserine and methylfolate.

### Claim 9 (depends on 1)

The method of claim 1, wherein providing the patient with a medical food composition comprises providing the patient with a medical food composition comprising phosphatidylserine and methylfolate, epigallocatechin gallate (EGCG) and quercetin.

### Claim 10

A method of treating a patient having a disruption in a prefrontal dopamine axis (Axis I) with a medical food, the method comprising:
determining that the patient has a disruption in the prefrontal dopamine axis based on the presence of one or more biomarkers indicating a disruption in the prefrontal dopamine axis; and
providing the patient with a medical food composition comprising phosphatidylserine and methylfolate that reduces degradation of dopamine and increases synthesis of dopamine.

### Claim 11

A method of treating a patient having a disruption in a limbic hyperactivity (Axis II) with a medical food, the method comprising providing the patient with a medical food composition comprising a first compound that increases brain mitochondrial activity and a second compound that increases the degradation and/or reuptake of catecholamines.

### Claim 12 (depends on 11)

The method of claim 11, further comprising determining that the patient has a disruption in the limbic hyperactivity axis based on the presence of one or more biomarkers indicating a disruption in the production or clearance of catecholamines in the brain.

### Claim 13 (depends on 11)

The method of claim 11, wherein providing comprises providing a medical food including S-adenosyl methionine and magnesium.

### Claim 14 (depends on 11)

The method of claim 11, wherein providing comprises providing a medical food including S-adenosyl methionine, magnesium, creatine and taurine.

### Claim 15 (depends on 11)

The method of claim 11, further comprising determining that the patient has a disruption in the limbic hyperactivity axis based on a polymorphism in one or more of: COMT, SERT (SLC6A4), or PKBP5.

### Claim 16

A method of treating a patient having a disruption in a limbic hyperactivity axis (Axis II) with a medical food, the method comprising:
determining that the patient has a disruption in the limbic hyperactivity axis based on the presence of one or more biomarkers indicating a disruption in the prefrontal dopamine axis; and
providing the patient with a medical food composition comprising a creatine, magnesium and taurine configured to increase brain mitochondrial activity and increase the degradation and/or reuptake of catecholamines.

### Claim 17

A method of treating a patient having a disruption in a cortical glutamate axis (Axis III) with a medical food, the method comprising providing the patient with a medical food composition comprising a combination of compounds that inhibits PLA2, reduces NMDA neurotoxicity and enhances BDNF function.

### Claim 18 (depends on 17)

The method of claim 17, further comprising determining that the patient has a disruption in the disruption in a cortical glutamate axis based on the presence of one or more biomarkers indicating a disruption in the calcium-dependent NMDA transmission.

### Claim 19 (depends on 17)

The method of claim 17, further comprising determining that the patient has a disruption in the disruption in a cortical glutamate axis based on the presence of a polymorphism in one or more of CACNA1C and BDNF indicating a disruption in the calcium-dependent NMDA transmission.

### Claim 20 (depends on 17)

The method of claim 17, wherein the medical food composition comprises docosahexaenoic acid (DHA) and cytidine diphosphate choline and one or more medium chain fatty acids.

### Claim 21 (depends on 17)

The method of claim 17, wherein the medical food composition comprises docosahexaenoic acid (DHA), cytidine diphosphate choline and decenoic acid.

### Claim 22

A method of treating a patient having a disruption in a cortical glutamate axis (Axis III) with a medical food, the method comprising:
determining that the patient has a disruption in the cortical glutamate axis based on the presence of one or more biomarkers indicating a disruption in the calcium-dependent NMDA transmission; and
providing the patient with a medical food composition comprising a combination of compounds that inhibits PLA2, reduces NMDA neurotoxicity and enhances BDNF function, the combination comprising docosahexaenoic acid (DHA) and cytidine diphosphate choline.

### Claim 23

A method of treating a patient having a disruption in a subcortical glutamate axis (Axis IV) with a medical food, the method comprising providing a biomarkers indicating an excess of glutamate or a deficiency of dopamine in a subcortical region with a medical food composition comprising sulphoraphane and N-acetylcysteine.

### Claim 24 (depends on 23)

The method of claim 23, further comprising determining that the patient has a disruption in the subcortical glutamate axis based on the presence of one or more biomarkers indicating an excess of glutamate or a deficiency of dopamine in a subcortical region.

### Claim 25 (depends on 23)

The method of claim 23, wherein the medical food further comprises Sarcosine.

### Claim 26 (depends on 23)

The method of claim 23, wherein the medical food further comprises ascorbate.

### Claim 27 (depends on 23)

The method of claim 23, further comprising determining that the patient has a disruption in the subcortical glutamate axis based on the presence of one or more biomarkers indicating an excess of glutamate or a deficiency of dopamine in a subcortical region based on the presence of a polymorphism in one or more of SLC1A1, OPRM1 and DBH genes.

### Claim 28 (depends on 23)

The method of claim 23, further comprising determining that the patient has a disruption in the subcortical glutamate axis based on the presence of one or more biomarkers indicating an excess of glutamate or a deficiency of dopamine in a subcortical region based on the presence of one or more biomarkers comprises identifying that the patient has the rs301430 G>T polymorphism in a SLC1A1 gene.

### Claim 29 (depends on 23)

The method of claim 23, wherein the medical food comprises a dose of between about 500 and about 2400 mg/daily of N-acetylcysteine and a dose of between about 5 and about 70 mg/daily of sulphoraphane.

### Claim 30

A method of treating a patient having a disruption in a subcortical glutamate axis (Axis IV) with a medical food, the method comprising:
determining that the patient has a disruption in the subcortical glutamate axis based on the presence of one or more biomarkers indicating an excess of glutamate or a deficiency of dopamine in a subcortical region comprising a polymorphism in one or more of SLC1A1, OPRM1 and DBH genes; and
providing the patient with a medical food composition comprising sulphoraphane at a dose of between about 5 and about 70 mg/daily and N-acetylcysteine at a dose of between about 500 and about 2400 mg/daily.
